Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01191320 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus
A Phase 2 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT01191320 is a Phase 2 study that has completed, run by Repros Therapeutics. The registered enrollment target is 102 participants.
The verdict
NCT01191320, a Phase 2 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect the investigative drug has on glycemic control in men with type 2 diabetes mellitus (T2DM) and secondary hypogonadism
Interventions
- DRUG Placebo
- DRUG Androxal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01191320
The ClinicalTrials.gov registry entry for NCT01191320 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01191320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01191320 about?
NCT01191320 is a clinical study titled "Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus". The purpose of this study is to determine the effect the investigative drug has on glycemic control in men with type 2 diabetes mellitus (T2DM) and secondary hypogonadism
What is the current status of trial NCT01191320?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2010-10. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01191320?
The interventions under investigation include: Placebo (DRUG), Androxal (DRUG).
Who is sponsoring clinical trial NCT01191320?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.